An agreement has been reached where Moderna will use Caris Life Sciences’ library of de-identified, multi-modal health data solutions. These solutions have been generated from whole exome sequencing, whole transcriptome sequencing, protein analyses, and claims data. This collaboration aims to strengthen the development strategies for Moderna’s oncology.
The strategies would include the facilitation of optimal clinical trial design, novel biomarkers discovery, and resistance mechanisms characterization. This partnership is expected to support Moderna’s oncology portfolio through clinical-genomics data from Caris’ suite of integrated precision medicine capabilities.
Caris Life Sciences is recognized for its expertise in precision medicine and molecular profiling. The company has reportedly created the largest clinical-genomic database, which is further enhanced by cognitive computing, to unravel the molecular complexity of diseases.
The company stands out as being the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES/WTS) for every patient. This positions Caris as a leader in its field and a valuable partner for Moderna.
The collaboration between Caris Life Sciences and Moderna is expected to have a significant impact on the field of cancer treatment with mRNA medicines. The mutual goal of both entities is to improve patient lives.
The combined molecular, data science, and therapeutics technologies of both organizations are anticipated to support the predictive modeling of patient responses to therapies. This collaboration could also potentially enhance the technical and regulatory success of Moderna’s innovative medicines.
Overall, this partnership between Moderna and Caris Life Sciences is set to advance the field of mRNA-based oncology therapeutics. By combining their respective strengths in therapeutics technologies, molecular profiling, and data science, the two entities aim to improve the probability of technical and regulatory successes, and ultimately, enhance patient outcomes in cancer treatment.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
